Research published in eBioMedicine confirmed that cagrilintide lowers body weight specifically through brain amylin receptors 1 and 3 (AMY1R and AMY3R), and these are distinct from the receptors that GLP-1 agonists activate
These findings align with previous research demonstrating the therapeutic potential of natural products like Cinnamaldehyde, Sarsasapogenin-AA13, Ginkgo biloba extracts, and active components of Andrographis paniculata in targeting these pathways for AD treatment [49, 89,90,91,92]
If that magnitude of benefit doesn't justify the cost and inconvenience, MIC B12 injections are not the right intervention
To date, clinical trials in humans remain limited, although several are underway or in the planning phase